Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1
- Conditions
- Myotonic Dystrophy Type 1 (DM1)
- Interventions
- Other: Dyspnea
- Registration Number
- NCT04835298
- Lead Sponsor
- CHU de Reims
- Brief Summary
Myotonic dystrophy type 1 (DM1) is one of the most common neuromuscular diseases in adults. As respiratory dysfunction is the most common cause of death in patients with DM1, a respiratory disease progression must be monitored combining symptom screening and respiratory function testing, in order to identify the appropriate time to initiate non invasive ventilation (NIV).
Dyspnea, one of the main respiratory symptoms, has been little studied in patients with DM1.
The main objective of this study is to provide the first multidimensional description of dyspnea in patients with DM1.
The secondary objectives are:
* To compare respiratory symptoms according to the presence or not of criteria from respiratory function testing to initiate NIV
* To assess associations between dyspnea and respiratory function testing
* To assess associations between dyspnea and number of Cytosine Thymine Guanine (CTG) repeats
* To assess associations between dyspnea and muscular strength
* To assess associations between dyspnea and BMI
* To assess associations between dyspnea and anxiety or depression
* To assess associations between dyspnea and cognitive impairment
* To assess associations between dyspnea and quality of life.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 34
- patient with myotonic dystrophy type 1 confirmed by genetic analysis
- with an age older than 18 years
- an ongoing or recent (i.e. within the last 4 weeks prior to study recruitment) medical condition, including pulmonary exacerbations
- patient already under non-invasive mechanical ventilation
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Myotonic dystrophy type 1 Dyspnea adult patients with myotonic dystrophy type 1
- Primary Outcome Measures
Name Time Method Dyspnea Month 6 Borg scale at rest and after 6 minute walking test
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chu Reims
🇫🇷Reims, France